Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M

Bristol-Myers SquibbTo mark World AIDS Day, the Bristol-Myers Squibb Foundation today announced 16 grants totaling $3.5 million for programs in Africa that strengthen HIV services for adolescents and the elderly, raise awareness and access to health care for women co-diagnosed with HIV and breast or cervical cancer, and build community capacity and integrate treatment for HIV/tuberculosis (TB) co-infection.

The grants, both new and extensions for ongoing programs, were awarded through the Foundation’s landmark Secure the Future® initiative, which brings community-based care and support to people with living with HIV in sub-Saharan Africa. Since its launch in 1999, Secure the Future has awarded more than $183 million in grants to more than 350 projects.

"The Bristol-Myers Squibb Foundation joins with our existing and new partners to continue working toward a world that is free of HIV," says John Damonti, president, Bristol-Myers Squibb Foundation. "Through these grants, the Foundation and its partners are helping to ensure that HIV-positive youth and the elderly in Africa continue to receive much-needed care and support, and that women who are co-infected with HIV and cervical or breast cancer have information and access to potentially lifesaving screening and treatment. In addition, given the close correlation between HIV infection and TB, it is essential that we work with our partners to continue strengthening community programs and approaches that integrate both diseases."

Adolescents and the elderly
Adolescents in Africa often have difficulty accessing treatment for HIV and other health and psychosocial services. In addition, stigma and other barriers result in many youth being lost to care even before beginning treatment or immediately after testing positive for HIV.

Africa also has a growing population of elderly people who are HIV-positive as a result of greater access to antiretroviral therapies and a general increase in the aging population. This trend has implications for policy, planning and practice. Most research and data have focused on the effects of the epidemic on children, youth and prime-age adults, but there is a need for studies that investigate patients 50 and older.

Grants for programs that address care and support of adolescents living with HIV will be implemented by Children’s Radio Project, South Africa; Sinomlando Project, South Africa; and AfricAid Zvandiri, Zimbabwe. Studies of HIV prevention practices among adults 50 and older and HIV/cancer co-infection among the elderly will be implemented by the University of Cape Town’s Institute of Ageing in Africa and Catholic University of Health and Allied Sciences, Tanzania.

HIV and Female Cancers
In sub-Saharan Africa, cervical and breast cancers are the leading causes of cancer death among women. The rate of cervical cancer among women living with HIV is three times higher than those who are not HIV-positive, primarily because of co-infection with the human papillomavirus (HPV), which causes cervical and other gynecological cancers. An estimated 60% to 80% of women in sub-Saharan Africa who are living with HIV are infected with HPV. The Bristol-Myers Squibb Foundation and Pink Ribbon Red Ribbon (PRRR), a global partnership fighting women’s cancers, have been working together to reduce the rate of female cancers among women who are co-infected with HIV.

Eight organizations have received grants that will continue to build knowledge about HIV and cancer, increase HIV/cervical/breast cancer screening and diagnosis efforts and strengthen the Foundation’s collaboration with PRRR. Programs will be implemented by Tanzania Youth Alliance; Medical Women Association of Tanzania; Mbeya HIV/AIDS Network, Tanzania; Tanzania Marketing and Communications; Mathiwos Wondu-YeEthiopia Cancer Society, Ethiopia; Doctors With Africa CUAMM, Tanzania; Sex Workers Education and Advocacy Task Force, South Africa; and Forum for African Women Educationalists Swaziland Chapter.

HIV and Tuberculosis
In countries with high levels of HIV, such as those in sub-Saharan Africa, about 80% of people with TB also have HIV. Globally, TB is among the deadliest diseases and a leading killer of people living with HIV. Since it was launched in 1999, the Foundation’s Secure the Future initiative has been committed to helping patients with TB who also have HIV. For the past three years, the Foundation has been collaborating with the World Health Organization’s (WHO) Global TB Program on ENGAGE-TB, a program to strengthen community-based care for patients who have TB and for those co-infected with HIV.

Grants to partners who are building capacity within communities for integrated HIV/TB screening, diagnosis and treatment will be implemented by Consortium of Christian Relief & Development Association, Ethiopia; National University of Lesotho Consuls Unit; and Grassroots Poverty Alleviation Program, Kenya.

About the Bristol-Myers Squibb Foundation
The mission of the Bristol-Myers Squibb Foundation is to help reduce health disparities by strengthening community-based health care worker capacity, integrating medical care and community-based supportive services, and mobilizing communities in the fight against disease.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]